Hepc ELISA kit (Human)

SKU: SEB979Hu

Size: 96Tests

# of Times Cited in literature: 20

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: Hepc

Target Full Name: Hepcidin

Alternative Names: HAMP; HFE2B; PLTR; LEAP1; Hepcidin Antimicrobial Peptide; Liver-expressed antimicrobial peptide 1; Putative liver tumor regressor

Target Species: Human

Uniprot: P81172

Gene ID: 57817

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human Hepc / Hepcidin

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 62.5-4,000pg/mL

Sensitivity: 26.4pg/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Hepcidin (Hepc) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Hepcidin (Hepc) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Hepcidin (Hepc). No significant cross-reactivity or interference between Hepcidin (Hepc) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Hepcidin (Hepc). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Hepcidin (Hepc). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Hepcidin (Hepc), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Hepcidin (Hepc) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Metabolic pathway;Endocrinology;Hematology;Genetic science;

References Citing This Product: Hepcidin and iron metabolism associated with cardiometabolic risk factors in children: A case-control study.

Hepcidin and iron metabolism associated with cardiometabolic risk factors in children: A case–control study

Maternal and cord blood hepcidin levels based on gestational weeks in term and preterm infants

Inflammatory anemia-associated parameters are related to 28-day mortality in patients with sepsis admitted to the ICU: a preliminary observational study

Relation of serum hepcidin levels and restless legs syndrome in chronic hemodialysis patients

Difference in iron metabolism may partly explain sex-related variability in the manifestation of Wilson's disease

Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease